Literature DB >> 25806342

The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer.

Massimo Di Maio1, Giorgio Vittorio Scagliotti1.   

Abstract

Entities:  

Year:  2015        PMID： 25806342      PMCID： PMC4367709          DOI： 10.3978/j.issn.2218-6751.2015.01.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  7 in total

1.  American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

Authors:  Lee M Ellis; David S Bernstein; Emile E Voest; Jordan D Berlin; Daniel Sargent; Patricia Cortazar; Elizabeth Garrett-Mayer; Roy S Herbst; Rogerio C Lilenbaum; Camelia Sima; Alan P Venook; Mithat Gonen; Richard L Schilsky; Neal J Meropol; Lowell E Schnipper
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

2.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Authors:  Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol
Journal:  Lancet       Date:  2014-06-02       Impact factor: 79.321

3.  Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

Authors:  Daniel D Karp; Luis G Paz-Ares; Silvia Novello; Paul Haluska; Linda Garland; Felipe Cardenal; L Johnetta Blakely; Peter D Eisenberg; Corey J Langer; George Blumenschein; Faye M Johnson; Stephanie Green; Antonio Gualberto
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

4.  Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).

Authors:  Adam Pavlicek; Maruja E Lira; Nathan V Lee; Keith A Ching; Jingjing Ye; Joan Cao; Scott J Garza; Kenneth E Hook; Mark Ozeck; Stephanie T Shi; Jing Yuan; Xianxian Zheng; Paul A Rejto; Julie L C Kan; James G Christensen
Journal:  Mol Cancer Ther       Date:  2013-10-09       Impact factor: 6.261

5.  Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Authors:  Corey J Langer; Silvia Novello; Keunchil Park; Maciej Krzakowski; Daniel D Karp; Tony Mok; Rebecca J Benner; Judith R Scranton; Anthony J Olszanski; Jacek Jassem
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

6.  Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.

Authors:  G V Scagliotti; I Bondarenko; F Blackhall; F Barlesi; T-C Hsia; J Jassem; J Milanowski; S Popat; J M Sanchez-Torres; S Novello; R J Benner; S Green; K Molpus; J-C Soria; F A Shepherd
Journal:  Ann Oncol       Date:  2014-11-13       Impact factor: 32.976

7.  Comprehensive genomic characterization of squamous cell lung cancers.

Authors: 
Journal:  Nature       Date:  2012-09-09       Impact factor: 49.962
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.